The Index is a portfolio of small and mid-cap biotechnology and pharmaceutical stocks listed on US stock exchanges that have one or more drugs in either Phase II or Phase III US FDA clinical trials. The Index includes stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion.
0.00
As of 08/15/2022
2022 © Stock Market MBA, Inc.